SEROFLO MULTIHALER (Cipla Australia Pty Ltd)

For the regular treatment of asthma, where the use of a combination product is appropriate. This may include:

• Patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids
• Patients who are symptomatic on current inhaled corticosteroid therapy.

For the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. SEROFLO MULTIHALER is not indicated for the initiation of bronchodilator therapy in COPD.